The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -50,332 | -130,253 |
| Depreciation and amortization of property and equipment | 2,702 | 4,491 |
| Amortization of finance lease right of use asset | 538 | 1,077 |
| Stock-based compensation | 9,759 | 21,188 |
| Accretion of discount on investments, net | 1,599 | 4,287 |
| Change in fair value of warrant liabilities | 0 | 0 |
| Prepaid expenses and other assets | -739 | -200 |
| Accounts payable and accrued expenses | -12,247 | 2,863 |
| Operating lease liabilities and right of use assets, net | 12 | 22 |
| Finance lease liability | 8 | 25 |
| Other liabilities | 0 | -80 |
| Net cash used in operating activities | -50,420 | -104,754 |
| Purchases of investments | 29,438 | 192,620 |
| Proceeds from maturities of investments | 123,000 | 166,760 |
| Purchases of property and equipment | -54 | 414 |
| Net cash provided by investing activities | 93,616 | -26,274 |
| Issuance of common stock pursuant to exercise of stock options | 0 | 0 |
| Return of related party short swing profits | 0 | 215 |
| Repurchase of restricted stock units to satisfy tax withholding | 67 | - |
| Net cash provided by financing activities | -67 | 215 |
| Net change in cash, cash equivalents and restricted cash | 43,129 | -130,813 |
| Cash and cash equivalents at beginning of period | 164,997 | - |
| Cash and cash equivalents at end of period | 77,313 | - |
ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. (RCKT)